Eur Rev Med Pharmacol Sci 2021; 25 (24): 7622-7625
DOI: 10.26355/eurrev_202112_27608

Editorial – Direct-acting antivirals therapy in HCV patients with HCC: lights and shadow

B. Rinaldi, V. Rosato, R. Galiero, E. Vetrano, M. Fasano, L. Rinaldi

Department of Experimental Medicine, Section of Pharmacology, University of Campania Luigi Vanvitelli, Naples, Italy. lucarinaldi@hotmail.it

Free PDF Download

To cite this article

B. Rinaldi, V. Rosato, R. Galiero, E. Vetrano, M. Fasano, L. Rinaldi
Editorial – Direct-acting antivirals therapy in HCV patients with HCC: lights and shadow

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 24
Pages: 7622-7625
DOI: 10.26355/eurrev_202112_27608

Keywords Related articles:

  1. Editorial – HCC in HCV patients and the direct acting antivirals: is there really a link?
  2. Editorial – Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents
  3. Effects of direct-acting antiviral therapy for patients with advanced hepatocellular carcinoma and concomitant hepatitis C—A population-based cohort study
  4. Impact of reimbursement limits on patient access to direct-acting antivirals in Italy: analysis of data from national registries
  5. Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensus